Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC
Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.
Memorial Sloan Kettering Cancer Center New York United States Alison Schram Beigene Springworks Us Food Drug Administration
Source: onclive.com